Lupin VISUfarma licenses YUVEZZI in Europe

Lupin (company)'s wholly-owned subsidiary VISUfarma has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a wholly-owned subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI, a once-daily eye drop for presbyopia, in the European Union, the United Kingdom, Switzerland, Norway, and Iceland. Under the agreement, VISUfarma will handle regulatory activities, commercialization, marketing, promotion, distribution, and sale of the product in these territories. The total potential consideration is up to 75 million euros, comprising a 20 million euro strategic investment in Visus through a Simple Agreement for Future Equity (SAFE) instrument and up to 55 million euros in regulatory and commercial milestone payments. Additionally, Tenpoint and Visus are eligible for tiered royalties based on net sales and sales milestone payments. YUVEZZI is the first and only approved once-daily dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. It has received U.S. FDA approval, and Tenpoint is preparing for its U.S. commercial launch. Tenpoint has also submitted a marketing application in the UK through the MHRA's International Recognition Procedure. Lupin CEO Vinita Gupta and Tenpoint CEO Henric Bjarke both expressed enthusiasm about the partnership, which strengthens Lupin's vision care franchise and expands its presence in European Union — European markets.